# UNLOXCYT (cosibelimab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cosibelimab

> The FDA approved UNLOXCYT (cosibelimab), sponsored by Fortress Biotech, Inc. (FBIO), on December 13, 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is UNLOXCYT (cosibelimab) FDA approved?

Yes. The FDA approved UNLOXCYT (cosibelimab), sponsored by Fortress Biotech, Inc. (FBIO), on December 13, 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma. SEC Form 8-K: "On December 13, 2024, Checkpoint Therapeutics ("Checkpoint"), a majority-controlled subsidiary of Fortress Biotech, Inc. (the "Company" or "Fortress"), announced that the U.S. Food and Drug Administration (the "FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC") who are not candidates for curative surgery or curative radiation." [Calendar and source filings](https://sec-api.dev/pdufa/cosibelimab)

Source: SEC Form 8-K, accession 0001558370-24-016294, https://www.sec.gov/Archives/edgar/data/1429260/000155837024016294/fbio-20241213x8k.htm (retrieved 2026-11-12). Last confirmed 2025-05-15. Cite: https://sec-api.dev/pdufa/cosibelimab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | UNLOXCYT (cosibelimab) |
| Codes |  |
| Sponsor | Fortress Biotech, Inc. (FBIO) https://sec-api.dev/companies/fbio/catalysts |
| Indications | [metastatic or locally advanced cutaneous squamous cell carcinoma](https://sec-api.dev/indications/metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma), metastatic or locally advanced cscc, with metastatic cutaneous squamous cell carcinoma, with metastatic or locally advanced cutaneous squamous cell carcinoma |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### Jul 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: metastatic or locally advanced cSCC.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015726): "In July 2024, the FDA accepted the Biologics License Application ("BLA") resubmission for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation and set a PDUFA goal date of December 28, 2024." https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm

### December 13, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: metastatic or locally advanced cutaneous squamous cell carcinoma.
- First seen 2024-12-16, last confirmed 2025-05-15.
- SEC Form 8-K (accession 0001558370-24-016294): "On December 13, 2024, Checkpoint Therapeutics ("Checkpoint"), a majority-controlled subsidiary of Fortress Biotech, Inc. (the "Company" or "Fortress"), announced that the U.S. Food and Drug Administration (the "FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC") who are not candidates for curative surgery or curative radiation." https://www.sec.gov/Archives/edgar/data/1429260/000155837024016294/fbio-20241213x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007878): "In December 2024, the FDA approved UNLOXCYT, also known as cosibelimab, our anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC") who are not candidates for curative surgery or radiation." https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-004154): "In December 2024, the FDA approved UNLOXCYT, also known as cosibelimab, our anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC") who are not candidates for curative surgery or radiation." https://www.sec.gov/Archives/edgar/data/1429260/000155837025004154/fbio-20250331xex99d1.htm
- SEC Form 10-K (accession 0001558370-25-004160): "In December 2024, we announced that Checkpoint had received approval for UNLOXCYT, which is the first and only programmed death-ligand 1 ("PD-L1") blocking antibody to receive U.S. Food and Drug Administration ("FDA") marketing approval for the treatment of adults with metastatic cutaneous squamous cell carcinoma ("cSCC") or locally advanced cSCC who are not candidates for curative surgery or curative radiation." https://www.sec.gov/Archives/edgar/data/1429260/000155837025004160/fbio-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-004160): "On December 13, 2024, our partner company, Checkpoint received approval from the FDA for UNLOXCYT (cosibelimab-ipdl), for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC") in adults who are not candidates for curative surgery or radiation." https://www.sec.gov/Archives/edgar/data/1429260/000155837025004160/fbio-20241231x10k.htm

### December 28, 2024: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: metastatic or locally advanced cutaneous squamous cell carcinoma.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015726): "We could achieve up to two more U.S. FDA approvals in the next nine months, and our next anticipated PDUFA goal date is December 28, 2024, for cosibelimab, an anti-PD-L1 antibody, for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC")." https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015726): "In July 2024, the FDA accepted the Biologics License Application ("BLA") resubmission for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation and set a PDUFA goal date of December 28, 2024." https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm
- SEC Form 10-Q (accession 0001558370-24-015740): "Cosibelimab's Biologics License Application ("BLA") is currently under review by the U.S. Food and Drug Administration ("FDA") and has a Prescription Drug User Fee Act ("PDUFA") goal date of December 28, 2024." https://www.sec.gov/Archives/edgar/data/1429260/000155837024015740/fbio-20240930x10q.htm
- SEC Form 10-Q (accession 0001558370-24-015740): "The resubmission has been accepted as a complete response to the complete response letter received in December 2023, and the FDA has set a PDUFA goal date of December 28, 2024." https://www.sec.gov/Archives/edgar/data/1429260/000155837024015740/fbio-20240930x10q.htm
- SEC Form 8-K (accession 0001558370-24-016294): "On December 13, 2024, Checkpoint Therapeutics ("Checkpoint"), a majority-controlled subsidiary of Fortress Biotech, Inc. (the "Company" or "Fortress"), announced that the U.S. Food and Drug Administration (the "FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC") who are not candidates for curative surgery or curative radiation." https://www.sec.gov/Archives/edgar/data/1429260/000155837024016294/fbio-20241213x8k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cosibelimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "UNLOXCYT (cosibelimab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cosibelimab

```bibtex
@misc{secapidev_pdufa_cosibelimab_20261116,
  title        = {UNLOXCYT (cosibelimab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cosibelimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cosibelimab_20261116","title":"UNLOXCYT (cosibelimab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cosibelimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
